• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by VectivBio Holding AG (Amendment)

    2/14/23 3:03:10 PM ET
    $VECT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VECT alert in real time by email
    SC 13G/A 1 schedule13ga.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*

     
     
    VectivBio Holding AG
     
     
    (Name of Issuer)

     
     
    Ordinary Shares
     
     
    (Title of Class of Securities)
     

     
    H9060V101
     
     
    (CUSIP Number)
     

     
    December 31, 2022
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     

     

     

     

     

     
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Global Healthcare Master Fund, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    1,515,087 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    1,515,087 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,515,087 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    2.42%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     

    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    1,515,087 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    1,515,087 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,515,087 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    2.42%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     

    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare Fund II, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    453,963 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    453,963 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    453,963 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.72%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     

    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare GP II, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    453,963 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    453,963 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    453,963 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.72%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     

    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare Fund III, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    567,567 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    567,567 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    567,567 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.90%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     

    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare GP III, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    567,567 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    567,567 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    567,567 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.90%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     


    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    2,536,617 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    2,536,617 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,536,617 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    4.04%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)


    CUSIP NO.
    H9060V101

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    2,536,617 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    2,536,617 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,536,617 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    4.04%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)


    CUSIP NO.
    H9060V101

    Item 1.
     
     
    (a)
    Name of Issuer

       
    VectivBio Holding AG
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    Aeschenvorstadt 36, 4051 Basel, Switzerland

    Item 2.
     
     
    (a)
    Name of Person Filing
       
     
    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Private Healthcare Fund II, LP
    Cormorant Private Healthcare GP II, LLC
    Cormorant Private Healthcare Fund III, LP
    Cormorant Private Healthcare GP III, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
         
       
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
     
    (c)
    Citizenship
       
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Private Healthcare Fund II, LP - Delaware
    Cormorant Private Healthcare GP II, LLC - Delaware
    Cormorant Private Healthcare Fund III, LP - Delaware
    Cormorant Private Healthcare GP III, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
     
    (d)
    Title of Class of Securities
         
       
    Ordinary Shares
     
     
    (e)
    CUSIP Number
       
    H9060V101



    CUSIP NO.
    H9060V101

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c)
    [ ]
    Insurance Company as defined in Section 3(a)(19) of the Act
     
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
     
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned***
       
     
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.


    CUSIP NO.
    H9060V101

     
    (b)
    Percent of Class
       
     
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote
         
     
       
    (ii)
    shared power to vote or to direct the vote
         
       
    (iii)
    sole power to dispose or to direct the disposition of
         



    CUSIP NO.
    H9060V101

       
    (iv)
    shared power to dispose or to direct the disposition of
         
     
       
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.
     
     
    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), Cormorant Private Healthcare Fund II, LP (“Fund II”) and Cormorant Private Healthcare Fund III, LP (“Fund III”), as reported herein. Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP II, LLC and Cormorant Private Healthcare GP III, LLC serve as the general partners of the Master Fund, Fund II and Fund III, respectively. Cormorant Asset Management, LP serves as the investment manager to the Master Fund, Fund II and Fund III. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare GP III, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
     
    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in an amendment to the Issuer's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on November 10, 2022, that there were 62,732,542 ordinary shares outstanding as of November 10, 2022.
     
     
    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].



    CUSIP NO.
    H9060V101
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     
    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group
     
    Not applicable.

    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Exhibits 
    Exhibit

    99.1
    Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on June 17, 2022.




    CUSIP NO.
    H9060V101

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
     
    February 14, 2023
     

     
    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
     
    By: Cormorant Global Healthcare GP, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT GLOBAL HEALTHCARE GP, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE FUND II, LP
     
    By: Cormorant Global Healthcare GP II, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE GP II, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE FUND III, LP
     
    By: Cormorant Global Healthcare GP III, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE GP III, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT ASSET MANAGEMENT, LP
     
    By: Cormorant Asset Management GP, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    /s/ Bihua Chen
     
    Bihua Chen





    Get the next $VECT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VECT

    DatePrice TargetRatingAnalyst
    12/13/2022$18.00Buy
    Jefferies
    7/1/2022$23.00Overweight
    Piper Sandler
    More analyst ratings

    $VECT
    Leadership Updates

    Live Leadership Updates

    See more
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments

    $VECT
    SEC Filings

    See more
    • SEC Form EFFECT filed by VectivBio Holding AG

      EFFECT - VectivBio Holding AG (0001836379) (Filer)

      7/24/23 12:15:14 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by VectivBio Holding AG

      EFFECT - VectivBio Holding AG (0001836379) (Filer)

      7/24/23 12:15:16 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by VectivBio Holding AG

      EFFECT - VectivBio Holding AG (0001836379) (Filer)

      7/24/23 12:15:18 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VECT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on VectivBio with a new price target

      Jefferies initiated coverage of VectivBio with a rating of Buy and set a new price target of $18.00

      12/13/22 9:20:32 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on VectivBio with a new price target

      Piper Sandler initiated coverage of VectivBio with a rating of Overweight and set a new price target of $23.00

      7/1/22 7:43:59 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink initiated coverage on VectivBio Holding with a new price target

      SVB Leerink initiated coverage of VectivBio Holding with a rating of Outperform and set a new price target of $28.00

      5/4/21 7:12:31 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VECT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VECT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • SEC Form SC 13G/A filed by VectivBio Holding AG (Amendment)

      SC 13G/A - VectivBio Holding AG (0001836379) (Subject)

      2/14/24 12:29:44 PM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by VectivBio Holding AG

      SC 13D - VectivBio Holding AG (0001836379) (Subject)

      7/7/23 4:21:49 PM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by VectivBio Holding AG

      SC 13G - VectivBio Holding AG (0001836379) (Subject)

      6/5/23 4:12:06 PM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VECT
    Financials

    Live finance-specific insights

    See more
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      - Transaction Advances Ironwood's Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 - - Ironwood to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of VectivBio for $17.00 per Share - - Ironwood to Host Conference Call and Webcast Today at 8:30 a.m. ET - Ironwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, an

      5/22/23 6:57:00 AM ET
      $IRWD
      $VECT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023

      BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the full year ended December 31, 2022 and provide a business update on Wednesday, April 19, 2023 at 8:00 a.m. ET. A live webcast will be accessible under ‘Events & Presentations' in the ‘Investors & Media' section of VectivBio's website at ir.vectivbio.com. An archived replay of the webcast will be available on VectivBio's website approximately two hours after the conference call and will be available for thirty days

      4/12/23 8:00:00 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care